Acceptance rate of post-placental plac ement of intrauterine devices during the SARS-CoV-2 (COVID-19) pandemic

Author(s)

Jacapenga, Rodolfo R. ; Surita, Fernanda ; Bahamondes, Luis ; Juliato, Cassia R. T.

• Document type: Journal article
• Source: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. N/A, p. 5-pg., 2023-02-20.

Abstract

Objective: To evaluate the acceptance rate of post-placental intrauterine device (PPIUD) placement during the SARS-CoV-2 (COVID-19) pandemic and to to assess factors associated with PPIUD acceptance.Methods: A cross-sectional study was conducted between August 2020 and August 2021. PPIUDs were offered to women scheduled for caesarean delivery or admitted in labour at the Women's Hospital of the University of Campinas. The study compared women according to whether they accepted or did not accept the IUD placement. The factors associated with PPIUD acceptance were analysed through bivariate and multiple logistic regression analyses.Results: We enrolled 299 women (15.9% of the deliveries that occurred during study period), aged 26.8 +/- 6.5 years; 41.8% were White, almost one third were primiparous, and 155/299 (51.8%) had a vaginal delivery. The PPIUD acceptance rate was 65.6%. The principal reason for refusal was the desire for another contraceptive (41.8%). Women with the highest likelihood of accepting a PPIUD were younger (< 30 years old has 1.7 more likely or 74% greater), those without a partner (3.4 times more likely) and those after vaginal delivery (1.7 times more likely or 69% greater)Conclusion: The COVID-19 does not affected the PPIUD placement. PPIUD is a viable alternative during crisis in which women has difficult to access health services. Younger women, those without a partner and after vaginal delivery were more likely to accept a PPIUD during the COVID-19 pandemic.SHORT CONDENSATION Post-placental IUDs are an alternative during periods of crisis like the COVID-19 pandemic. Younger women, those without a partner and after vaginal delivery were more likely to accept a PPIUD during the COVID-19 pandemic. (AU)

• FAPESP's process: 20/14899-9 - Evaluating various clinical aspects of the use of levonorgestrel intrauterine system 52mg (SIU-LNG)
• Grantee: Gabriela de Oliveira Paez
• Support Opportunities: Scholarships in Brazil - Scientific Initiation